On February 1, 1951, Henrietta Lacks, a 30-year-old Black tobacco farmer from Virginia, arrived at Johns Hopkins Hospital with abnormal bleeding. She was diagnosed with cervical cancer. During treatment, doctors removed samples of her tumor without her knowledge or consent. Those cells, designated HeLa, became the first immortal human cell line—reproducing indefinitely in laboratory conditions. Over seven decades, HeLa cells have been used in research that produced the polio vaccine, cancer treatments, HIV drugs, gene mapping, and tens of thousands of scientific papers. The global HeLa industry generated billions of dollars in pharmaceutical sales and research funding. Henrietta Lacks died eight months after diagnosis. Her family learned of HeLa's existence in 1975—and received no compensation until a private agreement was reached in 2023.
On February 1, 1951, Henrietta Lacks, a 30-year-old Black tobacco farmer and mother of five, took the segregated bus from her home in Turner Station, Maryland, to Johns Hopkins Hospital in Baltimore. She had been experiencing abnormal vaginal bleeding for months. Johns Hopkins was one of the only major hospitals in the region that treated Black patients, maintaining separate "colored" wards under the Jim Crow medical system that governed healthcare in Maryland and throughout much of the United States.
Dr. Howard Jones examined Lacks and immediately identified a mass on her cervix. He performed a biopsy. The pathology report confirmed an aggressive adenocarcinoma—an invasive cervical cancer that had likely been growing for some time. Lacks was admitted for radium treatment, the standard therapy at the time. During her treatment on February 8, 1951, Jones removed two tissue samples from her cervix: one from the tumor, one from adjacent healthy tissue. These samples were delivered to the tissue culture laboratory of Dr. George Otto Gey.
There is no indication in the medical record that Henrietta Lacks was informed that her tissues would be used for research. She signed a general consent form for treatment, standard practice at the time, but there was no separate disclosure about research use of excised tissues. This was not unusual in 1951—informed consent for research was not yet standard medical practice, particularly in hospitals that served poor and minority populations.
George Gey had been attempting to grow human cells in laboratory culture for decades. The goal was to create a permanent cell line that could be used to study cancer, test drugs, and conduct medical research without requiring constant biopsies from patients. Every previous attempt had failed—human cells would divide a few times, then die.
Henrietta Lacks' cells behaved differently. Within 24 hours, Gey's assistant Mary Kubicek noticed that the cells were thriving. They doubled approximately every 20 to 24 hours. They showed no signs of senescence—the normal process by which cells stop dividing after a certain number of replications. Gey designated the cell line "HeLa," using the first two letters of Henrietta's first and last names.
On February 11, 1952, Gey appeared on national television holding a vial of HeLa cells. He announced that science now possessed an immortal cell line that would revolutionize medical research. He referred to the donor only as "a woman who had just died of cancer." Henrietta Lacks' name was not mentioned publicly. Her family, who lived less than 20 miles from Johns Hopkins, learned nothing of this development.
"The cells from the woman's tumor behaved in a very peculiar way. They grew like nothing anyone had ever seen before, doubling their numbers every twenty-four hours, stacking hundreds thick in layers."
Rebecca Skloot — The Immortal Life of Henrietta Lacks, 2010Gey freely shared HeLa cells with researchers around the world. He never patented the cell line. He never sought personal profit from its distribution. By all accounts, Gey believed the cells should be available to any scientist who could use them to fight disease. Within a year, HeLa cells were being shipped to laboratories in multiple countries.
The scale of distribution expanded dramatically when Microbiological Associates, a Bethesda, Maryland company founded in 1949, began mass-producing HeLa cells in 1952. The company grew the cells in large roller drums and shipped them to laboratories worldwide. By 1954, Microbiological Associates was producing an estimated six trillion HeLa cells per week. The company charged for the cells. Proceeds went to the company and its shareholders. Neither Henrietta Lacks nor her family received any compensation.
HeLa cells arrived at precisely the moment they were needed most. In the early 1950s, polio epidemics were terrorizing American communities. Jonas Salk was racing to develop a vaccine, but he needed vast quantities of human cells to grow the poliovirus for testing and production. HeLa provided the solution.
The National Foundation for Infantile Paralysis—the organization that funded polio research through the March of Dimes—established a cell production facility at Tuskegee Institute specifically to supply HeLa cells for vaccine development. The choice of Tuskegee was not coincidental. It was a historically Black institution, and Henrietta Lacks was a Black woman, though her identity remained concealed. The research took place at the same institution that was simultaneously conducting the Tuskegee Syphilis Study, in which hundreds of Black men were deliberately left untreated for syphilis so researchers could study the disease's natural progression.
After the polio vaccine, HeLa cells contributed to the development of treatments for leukemia, influenza, hemophilia, Parkinson's disease, and HIV/AIDS. They were sent into space to test whether human cells could survive zero gravity. They were used to study the effects of radiation, toxins, and pharmaceuticals. They became the standard tool for virology research, gene mapping, and in vitro fertilization techniques.
By the 1960s, HeLa had become the most widely used human cell line in medical research. Scientific papers citing HeLa began appearing at a rate of hundreds per year. Biotech and pharmaceutical companies incorporated HeLa into product development pipelines. The cells were generating value measured in millions, then billions, of dollars.
Henrietta Lacks died on October 4, 1951, eight months after her diagnosis. An autopsy revealed that her cancer had metastasized throughout her body—to her lungs, liver, kidneys, and brain. She was buried in an unmarked grave in Clover, Virginia, near her mother's gravesite. Her husband, David "Day" Lacks, was left to raise five children: Lawrence (16), Elsie (12, institutionalized with developmental disabilities), David Jr. (4), Deborah (2), and Joseph (1).
The family struggled financially. They moved into relatives' homes in Baltimore. The children grew up without health insurance, in poverty. Day Lacks rarely spoke about Henrietta. For 24 years, no one told the family that Henrietta's cells were alive.
In 1973, researchers contacted the Lacks family asking for blood samples. The stated purpose was genetic research related to cancer. Family members, confused about why researchers were interested in them decades after Henrietta's death, complied. Only then did they begin to understand that Henrietta's cells had been growing in laboratories around the world.
Deborah Lacks, Henrietta's youngest daughter, spent much of her adult life trying to understand what had happened to her mother and what it meant that her cells were immortal. She struggled with the psychological burden of knowing her mother's cells were in laboratories, vaccines, and research projects around the world—including experiments Deborah found morally troubling. She collaborated with science writer Rebecca Skloot, who spent a decade researching Henrietta's story.
Deborah died in 2009, one year before Skloot's book was published. She never saw the public recognition that followed.
In 1990, the California Supreme Court decided Moore v. Regents of the University of California, a case with direct implications for the Lacks family. John Moore's physician had removed his spleen to treat leukemia, then used cells from the spleen to develop a patented cell line estimated to be worth $3 billion. Moore sued for a share of the profits, arguing he had property rights in his own tissues.
The court ruled against Moore. It held that once tissues are removed from the body, the patient has no ownership claim to them or to products developed from them. The decision reasoned that allowing property claims would hinder medical research and create a chaotic market for body parts. The physician was found to have violated informed consent obligations by not disclosing his research and commercial interests, but Moore received no share of the cell line's value.
"To impose a duty on scientists to investigate the consensual pedigree of each human cell sample would cripple large areas of scientific and medical research."
Moore v. Regents of the University of California — California Supreme Court, 1990The Moore decision established the legal framework that made it difficult for the Lacks family to claim property rights in HeLa. Even if Henrietta had been alive to sue in 1951—and even if informed consent standards had existed at that time—the precedent suggested courts would not recognize an ownership claim to tissues after removal.
Federal regulations governing human subjects research, known as the Common Rule (45 CFR 46), were first codified in 1981 in response to revelations of research abuses including the Tuskegee Syphilis Study. The regulations require informed consent and institutional review board approval for research involving human subjects. However, the Common Rule has a significant gap: it generally does not apply to research using previously collected biological specimens if those specimens cannot be linked back to identifiable individuals.
This exception meant that research using HeLa cells did not require Lacks family consent, since the cells themselves—separated from any identifying information—were not considered "human subjects" under the regulatory definition.
HeLa cells reproduce so aggressively that they have contaminated hundreds of other cell lines. Even a small number of airborne HeLa cells landing in another cell culture can overtake and replace the original cells within weeks.
In 1966, geneticist Stanley Gartler presented evidence that 18 of the most commonly used cell lines were actually HeLa. They all shared a rare genetic marker—glucose-6-phosphate dehydrogenase type A—found primarily in people of African ancestry. The cell lines had supposedly come from patients of European and Asian descent. Gartler's conclusion was that all 18 lines had been contaminated with or completely replaced by HeLa.
The scientific community initially resisted Gartler's findings. Researchers had built careers on work using these cell lines. Acknowledging contamination would mean acknowledging that years of published research might be invalid. Follow-up studies in the 1970s and 1980s confirmed the problem was even more extensive than Gartler had shown. Estimates suggest 10 to 20 percent of cell lines in use have been contaminated with HeLa.
The contamination represented millions of dollars in wasted research funding and raised fundamental questions about the validity of thousands of published studies. It also meant that Henrietta Lacks' cells had spread even further than anyone realized—present in laboratories that believed they were working with entirely different cell lines.
Rebecca Skloot's 2010 book The Immortal Life of Henrietta Lacks brought Henrietta's story to mainstream attention. The book spent over 200 weeks on the New York Times bestseller list and was translated into more than 25 languages. It was adapted into an HBO film in 2017 starring Oprah Winfrey as Deborah Lacks.
Public pressure increased on Johns Hopkins Hospital and the National Institutes of Health to acknowledge the Lacks family. In 2013, NIH Director Francis Collins met with family representatives after NIH-funded researchers published the complete HeLa genome without consulting the family. The publication revealed identifiable genetic information about Henrietta's living descendants, raising privacy concerns.
Collins negotiated an agreement giving Lacks family representatives a role in decisions about access to HeLa genomic data stored in NIH databases. The agreement was unprecedented—the first time a research institution formally recognized a tissue donor's family as stakeholders in research decisions. However, the agreement did not include financial compensation.
Johns Hopkins released a statement in 2013 acknowledging that informed consent practices in 1951 "were very different than they are today" and expressing gratitude to Henrietta Lacks and her family. The hospital noted that it had never sold or profited from HeLa cells—a technically accurate statement, since Johns Hopkins is a nonprofit research institution. However, the statement did not address the billions of dollars generated by commercial entities that had mass-produced and sold HeLa.
On October 4, 2021—the 70th anniversary of Henrietta Lacks' death—her descendants filed a federal lawsuit in Baltimore against Thermo Fisher Scientific, a Massachusetts-based biotechnology company with approximately $40 billion in annual revenue. The complaint alleged that Thermo Fisher had unjustly enriched itself by mass-producing and selling HeLa cells and HeLa-derived products without the family's consent.
The lawsuit did not rely on property rights arguments foreclosed by the Moore decision. Instead, it argued that Thermo Fisher's ongoing commercial use of HeLa constituted a continuing violation of Maryland statutory law prohibiting unauthorized use of a person's name or likeness for commercial benefit, and that the company had been unjustly enriched at the family's expense.
The complaint detailed Thermo Fisher's acquisition history, noting that the company had purchased Life Technologies in 2014. Life Technologies had previously acquired Microbiological Associates—the original company that began mass-producing HeLa in 1952. The lawsuit argued that Thermo Fisher had inherited both the commercial benefits and the legal obligations associated with HeLa.
"It is unjust and it is time for Thermo Fisher and all others who have benefited from Henrietta Lacks' tissue to cease their commercialization and to compensate the Lacks family."
Ben Crump, Lacks family attorney — Press statement, October 2021In August 2023, the parties jointly announced they had reached a confidential settlement. Terms were not disclosed. Ben Crump, the attorney representing the Lacks family, described the settlement as "transformative" and stated it represented recognition of the family's long struggle for acknowledgment and compensation. Thermo Fisher issued a statement expressing respect for the Lacks family and noting the company's commitment to bioethical standards.
In addition to the Thermo Fisher settlement, the Lacks family reached a separate agreement with another biotech company. The existence and terms of that settlement have not been fully disclosed.
The 2023 settlements represented the first financial compensation to the Lacks family, 72 years after Henrietta's cells were taken without her knowledge or consent.
The HeLa case raises questions that remain incompletely resolved. Should patients have property rights in tissues removed during medical treatment? Should families of tissue donors receive compensation when those tissues generate commercial value? How should the law balance the interests of research, the pharmaceutical industry, and individual rights?
Current federal regulations still do not require consent for research use of previously collected de-identified biological specimens. The 2018 revision of the Common Rule addressed some tissue research issues but maintained the exception for de-identified materials. This means researchers can continue to use banked tissues without donor consent, as long as those tissues are not linked to identifiable individuals.
Several states have enacted their own regulations. California now requires specific consent for commercial use of tissues. Maryland, where Johns Hopkins is located and where Henrietta Lacks received treatment, has not enacted comparable protections.
The question of whether medical research should proceed differently because of what happened to Henrietta Lacks has divided ethicists, researchers, and legal scholars. Some argue that imposing consent requirements for research using de-identified tissues would create insurmountable barriers to medical progress. Others contend that the lack of such requirements perpetuates the exploitation that characterized mid-20th century medicine, particularly the exploitation of Black patients and other vulnerable populations.
Johns Hopkins has named a building after Henrietta Lacks. The Smithsonian Institution includes her story in its National Museum of African American History and Culture. Multiple universities offer courses examining the ethical issues raised by HeLa. These forms of recognition are symbolically significant but do not resolve the structural questions about tissue rights, consent, and compensation.
The Henrietta Lacks case cannot be separated from the context of American medical racism. Johns Hopkins maintained segregated wards in 1951. The hospital provided care to Black patients in exchange for access to their bodies for research and teaching—a transaction that was not explicitly disclosed or framed as an exchange of benefits.
This was not unique to Johns Hopkins. Medical schools and research hospitals throughout the segregated South and in Northern cities operated under similar models. Black patients, poor patients, and incarcerated patients were disproportionately used as research subjects without meaningful consent. The Tuskegee Syphilis Study, conducted from 1932 to 1972, is the most infamous example, but it was part of a broader pattern.
Between 1946 and 1948—just three years before Henrietta Lacks was treated at Johns Hopkins—U.S. Public Health Service researchers deliberately infected Guatemalan prisoners, soldiers, and psychiatric patients with syphilis and gonorrhea without consent. Some of the same scientists involved in the Guatemala experiments later worked on the Tuskegee study.
These practices were not aberrations. They were enabled by institutional structures, professional norms, and legal frameworks that treated certain populations as available for research without requiring the consent standards applied to other patients.
Henrietta Lacks was treated in a system designed to extract value from Black patients' bodies while providing minimal information and no compensation. The fact that her cells generated billions of dollars in commercial value while her family struggled to afford medical care is not an unfortunate side effect of that system. It was a predictable outcome of it.
The documented record establishes several facts without ambiguity:
Henrietta Lacks' tumor cells were removed during treatment at Johns Hopkins Hospital in February 1951 and given to researcher George Gey without her knowledge or consent. This is confirmed by hospital records, Gey's laboratory records, and later testimony from physicians involved.
Those cells became the HeLa cell line, the first immortal human cell line and the most widely used cells in medical research history. This is confirmed by thousands of published scientific papers and the testimony of researchers across seven decades.
HeLa cells contributed to the development of the polio vaccine, cancer treatments, HIV drugs, gene mapping, and numerous other medical advances. They have been cited in more than 75,000 scientific publications. These contributions are documented in the scientific literature and acknowledged by research institutions including the National Institutes of Health and the National Academy of Sciences.
Commercial entities including Microbiological Associates (later part of Life Technologies, acquired by Thermo Fisher Scientific) mass-produced and sold HeLa cells for profit beginning in 1952. This is documented in corporate records, scientific supply catalogs, and the 2021 lawsuit.
The Lacks family received no compensation for 72 years. They learned of HeLa's existence in 1975, 24 years after Henrietta's death. These facts are confirmed by family testimony and researcher correspondence.
In 2023, the Lacks family reached confidential settlements with Thermo Fisher Scientific and at least one other company. The terms are not public, but both parties acknowledged the settlements occurred.
What remains contested is not whether these events occurred, but how they should be evaluated and what legal and ethical obligations follow from them. Institutions and companies have argued that practices acceptable in 1951 should not be judged by 2023 standards, that informed consent was not required at the time, and that no laws were broken. The Lacks family and their advocates have argued that the absence of legal protections in 1951 does not make the taking ethical, and that continued commercial use in the 21st century cannot be defended by 1950s norms.
Both positions have support in legal doctrine and ethical philosophy. The settlements represent a pragmatic resolution, but they do not resolve the underlying questions about tissue rights, informed consent, and who benefits when human biological materials become commercial products.
Henrietta Lacks' cells continue to be used in laboratories around the world. They remain commercially available from multiple suppliers. Research using HeLa continues to produce published papers, patents, and pharmaceutical products. The scientific contribution is undeniable. So is the exploitation. These facts coexist in the historical record, documented in hospital files, laboratory notebooks, corporate earnings reports, and the lived experience of the Lacks family.